The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...
The following is a summary of “Efficacy and Hypoglycemia Profile of Once-Weekly Insulin Icodec vs. Once-Daily Comparators ...
Dexcom (Nadsaq:DXCM) announced today that it launched a new multi-region report evaluating type 2 diabetes treatments.
We are thrilled to announce our collaboration with Abbott, integrating its world-leading FreeStyle Libre technology 2 as our first CGM partner, marking a significant milestone as we bring our ...
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced the ...
Tandem Diabetes Care announced today that it launched its next-generation Control-IQ+ automated insulin delivery algorithm in ...
DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe ...
Hosted on MSN6mon
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study GoalsThe QWINT-1 study compared efsitora to daily injections of Sanofi’s SNY Lantus (insulin glargine) for 52 weeks in T2D patients using basal insulin for the first time. The QWINT-3 study compared ...
Brazil's National Health Surveillance Agency (Anvisa) has approved the drug Awiqli, produced by the pharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results